A high-throughput screening method for phosphodiesterase inhibitors

By constructing a cell line that is stable and highly expressed in variant luciferase, using fluorescence intensity reaction to screen phosphodiesterase inhibitors, the problems of labor-intensive and cost-effective screening methods in the prior art are solved, and low-cost and high-throughput Screening improves screening efficiency and security.

CN117187343BActive Publication Date: 2024-11-01QINGDAO UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311146827.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-06
Publication Date
2024-11-01
Estimated Expiration
2043-09-06

AI Technical Summary

Technical Problem

The existing phosphodiesterase inhibitor screening methods have the disadvantages of labor-intensive and high cost, and are not suitable for high-throughput screening. The use of radioisotopes is harmful to health and the environment. Short-wavelength light of fluorescence resonance energy transfer is cytotoxic. , limiting deep tissue imaging.

Method used

Using firefly luciferase biosensor technology, a cell line with stable and highly expressed variant luciferase was constructed. The phosphodiesterase inhibitor was screened by detecting the cAMP or cGMP levels in the cell, and the fluorescence intensity reaction screening tool was used to achieve low cost. High-throughput screening method.

Benefits of technology

The screening of phosphodiesterase inhibitors suitable for high-throughput screening is achieved, which improves screening efficiency and safety, reduces experimental costs, and does not involve radioactive materials, enhancing the credibility of detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117187343B_ABST
    Figure CN117187343B_ABST
Patent Text Reader

Abstract

The present invention relates to a phosphodiesterase inhibitor and a high-throughput screening method. Phosphodiesterase (PDE) is related to various physiological activities such as emotions, memory and cognitive functions, and is an important disease target. The existing screening methods for phosphodiesterase inhibitors have technical defects such as high cost and inability to achieve high-throughput screening. The present invention provides a low-cost, high-throughput screening method, by transfecting HEK293T cells with a luciferase expression vector, so that a single, stable, high-expression variant luciferase binding to cAMP or cGMP is used as a screening model, and compounds with inhibitory activity are quickly screened by fluorescence intensity, and the inhibitory active compound is added to the PDE monomer protein to determine the subtype and pharmacodynamic activity targeted by the PDE inhibitor. The above method uses living cells as a research model, which is closer to the physiological activity in vivo, can achieve low-cost high-throughput screening, and has important application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of active compound screening, and particularly relates to a high-throughput screening method for phosphodiesterase inhibitors. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Phosphodiesterase (PDE) is a hydrolase that regulates the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in cells. Mammalian phosphodiesterases can be divided into 11 subtypes (PDE1-11) based on structural similarity, hydrolysis characteristics, and cellular and subcellular distribution. Among them, PDE4, 7, and 8 mainly hydrolyze cAMP, PDE5, 6, and 9 specifically hydrolyze cGMP, and other PDEs have no selectivity for either. In terms of function, cAMP and cGMP are important second messengers in cells. They are involved in the regulation of central nervous system processes, such as the establishment of neural circuits and neuronal apoptosis, and are closely related to emotions, memory, and cognitive functions. Therefore, phosphodiesterase, as one of the key enzymes regulating its content, is closely related to the occurrence and development of many diseases. Phosphodiesterase inhibitors PDEi have become an important target for new drug development.

[0004] To obtain effective PDEi lead compounds, it is particularly important to choose an appropriate screening method. Currently, the screening methods for PDE inhibitors mainly include 3 H-adenine pre-labeling, enzyme-linked immunosorbent assay (ELISA), fluorescence resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET), and PDE-Glo TM Phosphodiesterase assay. Some of these methods have undergone many years of evolution and have matured, become recognized and widely used, while others were proposed in recent years and are still in the exploratory stage.

[0005] 3 The H-adenine pre-labeling method is mainly based on labeling the hydrolysis substrate of phosphodiesterase, cAMP or cGMP, with radioactive isotopes, and measuring the radioactivity after the reaction to reflect the amount of remaining substrate and thus detect the activity of the enzyme. 3 The H-adenine pre-labeling method has the advantages of high sensitivity and wide dynamic range, and can detect the effect of phosphodiesterase activity on substrate amount under normal physiological conditions. 3The use of H-adenine pre-labeling has an unavoidable problem, which is the safety of radioisotopes. Radioisotopes are considered harmful to human health and the environment, which makes this method extremely demanding in experimental conditions. In addition, labor-intensive, expensive and difficult to obtain continuous dynamic data are also disadvantages of this method.

[0006] ELISA is based on the concept of antigen-antibody reaction, which represents the chemical interaction between antibodies produced by white blood cells B cells and antigens. Therefore, by utilizing this reaction, ELISA allows highly sensitive and selective quantitative / qualitative analysis of antigens, and can be used to detect the amount of cAMP or cGMP after the reaction. ELISA is simple to operate, has the characteristics of high sensitivity and high specificity, and the experiment does not involve radioactive substances, which is safer. But at the same time, the biggest disadvantage of ELISA is its high cost. The antibodies themselves are expensive and unstable in nature, and have high requirements for transportation and storage. In addition, due to insufficient clogging of the surface of the microtiter plate where the antigen is fixed, the possibility of false positive or negative results in ELISA experiments is high.

[0007] FRET is a physical phenomenon in which a donor fluorophore in an excited state non-radiatively transfers its excitation energy to a neighboring acceptor fluorophore, causing the acceptor to emit its characteristic fluorescence. In contrast, BRET using luciferase rather than fluorescent proteins as donors is a more sensitive technique for plate-based assays because luciferase does not require laser excitation but instead emits light upon oxidation of the substrate molecule. FRET or BRET detection has higher spatial and temporal resolution than antibody-based methods. FRET sensors typically use blue or green light for excitation, however, these short-wavelength lights have high energies per photon, which makes them unsuitable for long-term imaging due to their cytotoxicity. In addition, the penetration depth of these lights is not long enough for deep tissue imaging or animal imaging. These issues and high costs limit the use of such methods.

[0008] PDE Glo TM The phosphodiesterase assay is a fluorescent high-throughput screening method. In the assay of this kit, cNMP binds to the inactive protein kinase A holoenzyme, and the regulatory subunit undergoes a conformational change to release the catalytic subunit. The free catalytic subunit then catalyzes the transfer of the terminal phosphate of ATP to the protein kinase A substrate, consuming ATP in the process. Using a luciferase-based kinase The reagent measures the level of remaining ATP. When PDE hydrolyzes cNMP, less protein kinase A is activated and more ATP is available for the luciferase reaction. As a result, luminescence increases. Therefore, luminescence is proportional to the remaining ATP level, and the remaining ATP level is proportional to the PDE level. Compared to all the methods described previously, PDE Glo TMThe phosphodiesterase assay has a significant feature, that is, it can directly reflect the effect of the sample on the phosphodiesterase activity, without having to infer whether the sample has inhibitory activity on PDE by observing the changes in cAMP or cGMP levels. However, the reagents required for this method are very expensive, and the enzyme activity experiment also has high requirements for the storage of reagents and experimental conditions, which makes this method unsuitable for high-throughput screening of phosphodiesterase inhibitors.

[0009] In summary, there are many methods currently used for screening phosphodiesterase inhibitors, but they all have disadvantages such as being labor-intensive and costly to a greater or lesser extent, and are not suitable for high-throughput screening. Therefore, establishing an effective and cost-effective high-throughput screening method for phosphodiesterase inhibitors is of great significance for the research and development of this type of new drugs. Summary of the invention

[0010] There are many methods currently used for screening phosphodiesterase inhibitors, but they all have disadvantages such as labor-intensiveness and high cost to a greater or lesser extent, and are not suitable for high-throughput screening. Based on firefly luciferase biosensor technology, the present invention successfully constructed a cell screening method for cAMP and cGMP. This method is relatively low in cost and suitable for high-throughput screening.

[0011] The present invention first provides a high-throughput screening method for phosphodiesterase inhibitors, constructing a cell line that stably and highly expresses variant luciferase as a screening tool, wherein there are two types of variant luciferases that specifically bind to cAMP and cGMP, respectively; after adding a test compound to the cells, the phosphodiesterase inhibitors are screened by detecting the substrate level in the cells.

[0012] Taking a cell line that highly expresses a variant luciferase that specifically binds to cAMP as an example, the screening principle is explained: in the screening tool designed by the present invention, the introduced cAMP-specific plasmid expresses a variant luciferase, which is in an inactive conformation when not bound to intracellular cAMP, but changes to an active conformation after binding to cAMP, and can react with the substrate luciferin added later to produce fluorescence, so the fluorescence intensity is proportional to the intracellular cAMP content; the same is true for the cGMP-specific plasmid.

[0013] The present invention constructs two cell models, which can reflect the level of cAMP or cGMP by fluorescence intensity, to achieve the screening of phosphodiesterase inhibitors. The specific steps of the screening method are as follows:

[0014] (1) constructing an expression vector of a variant luciferase, and transfecting the expression vector into normal cells, wherein the variant luciferase can specifically bind to cAMP or cGMP in the cells;

[0015] (2) Screening a cell line that stably and highly expresses the variant luciferase, adding the test compound for culturing, and detecting the cAMP or cGMP content in the cells.

[0016] In step (1), the expression vector may be a bacterial plasmid, bacteriophage, yeast plasmid, plant cell virus, mammalian cell virus or other vector well known in the art; in a preferred embodiment, it is a bacterial plasmid, an adenovirus vector or a lentivirus vector; in one embodiment provided by the present invention, a plasmid containing a variant luciferase expression cassette is used, and the plasmid can simultaneously achieve luciferase transfection and expression, and those skilled in the art can judge the expression changes of cAMP and cGMP in cells based on the cell fluorescence intensity and measure them.

[0017] Furthermore, during the transfection process of the above-mentioned expression vector, the expression content of cAMP and cGMP in the cells can be increased by adding cAMP and cGMP agonists: the variant luciferase substrate is D-Luciferin (the same as that used for cAMP and cGMP), which is diluted with DMEM culture medium and then added to the transfected cells for culture. A specific example of the cAMP agonist is Forskolin, and a specific example of the cGMP agonist is S-Nitroso-N-acetyl-DL-penicillamine (SNAP); the purpose of introducing the above-mentioned agonists is to increase the background cAMP and cGMP levels in the cells so as to improve the sensitivity of the detection method.

[0018] The normal cells should be human cells. Considering the convenience of conducting experiments, the cells should preferably have strong proliferation ability and be easy to introduce foreign genes, such as HEK293T cell line.

[0019] In the above step (2):

[0020] When the expression vector is a luciferase expression vector, the cAMP and cGMP contents can be determined by fluorescence intensity detection, such as a fluorescence spectrophotometer, an enzyme-labeled instrument, etc., and those skilled in the art can make routine selections of detection methods based on factors such as cost; in an implementation method in which detection is performed by an enzyme-labeled instrument, the detection steps are as follows: a positive drug and a test compound are respectively added to a cell line expressing a variant luciferase, and the fluorescence intensities of the test compound group and the positive drug group are compared. A higher fluorescence intensity indicates that the test compound has a stronger phosphodiesterase inhibitory activity.

[0021] Among the 11 subtypes of PDE, PDE4, 7 and 8 specifically hydrolyze cAMP, and PDE5, 6 and 9 specifically hydrolyze cGMP. The above screening method provided by the present invention screens inhibitors with subtypes related to cAMP and cGMP. In order to further clarify which PDE subtype the screened compounds can act on, the screening method also includes the following steps: constructing recombinant plasmids encoding different PDE subtypes, allowing them to highly express PDE proteins of each subtype in Escherichia coli, and using protein purification technology to obtain monomers of each subtype of protein; the above active compounds obtained by the fluorescence intensity screening act on PDE proteins of each subtype, and the amount of hydrolyzed substrate is determined by HPLC technology, thereby confirming the PDE subtype acted by the compound.

[0022] The above screening method provided by the present invention uses active cells as a model for screening, which is closer to the physiological environment when the compound exerts its efficacy, and the screening results have higher credibility. In addition, the above screening method can achieve the effect of simultaneous detection of multiple samples based on conventional detection means such as microplate readers, and is a low-cost high-throughput screening method. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0024] Figure 1 The construction principle of the screening tool in the present invention;

[0025] in, Figure 1 A is the recombinant plasmid used to construct the screening tool;

[0026] Figure 1 B is the working principle of variant luciferase. DETAILED DESCRIPTION

[0027] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0028] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should also be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0029] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0030] Example 1

[0031] In this embodiment, a model and a screening method for specific PDE inhibitors are specifically provided. Figure 1 The recombinant plasmid used to construct the screening tool ( Figure 1 A) and the mechanism of action of the variant luciferase expressed by the plasmid ( Figure 1 B). The plasmid encodes a firefly luciferase variant with a cAMP binding domain inserted into the hinge region of the enzyme. This causes the luciferase that is not bound to cAMP to be in an inactive conformation and unable to bind to the substrate luciferin. After the luciferase binds to cAMP, the conformation changes, allowing it to bind to D-Luciferin, greatly increasing the fluorescence intensity. Therefore, when the cells are successfully transfected and express the variant luciferase, if the fluorescence value of the experimental group is higher than that of the control group, it indicates that the test substance can effectively increase the cAMP content in the cell. Given that PDEs are cAMP hydrolases, it is possible that the compound inhibits the activity of PDEs, and the next step of verification can be carried out.

[0032] In the following examples, the expression vector of the variant luciferase is a commercially available product, and the purchase information is as follows:

[0033] (1) The plasmid pGloSensor that expresses a variant luciferase that specifically binds to cAMP was used in the experiment TM -22FcAMP Plasmid map (#GU174434) was purchased from Promega;

[0034] (2) The plasmid pGloSensor that can express a variant luciferase that specifically binds to cGMP was used in the experiment TM -42FcGMP Plasmid map was purchased from Promega (Part ID#CS177001).

[0035] 1. Screening model construction and screening method

[0036] (I) Construction of a cell model expressing luciferase that can specifically bind to cAMP to screen for cAMP-specific PDE inhibitors:

[0037] 1. Cell culture: The frozen HEK293T cells were revived and cultured in high-glucose DMEM (containing 10% FBS + 1% double antibody) medium. After 2-3 days of trypsin digestion and passage, the cells were cultured in 6 cm culture dishes when they were in good condition.

[0038] 2. Cell plasmid transfection: When the cells are about 40%-60% confluent in the culture dish, perform plasmid transfection.

[0039] (1) Take 50ul of Opti-MEM culture medium and mix with 4ul of lipofectamine 2000 reagent, mark it as tube 1, and leave it at room temperature for 5 minutes;

[0040] (2) Mix 50ul of Opti-MEM culture medium and 10ul of pGloSensor-22F cAMP plasmid (concentration is about 1000ng / μL), mark it as tube 2, and leave it at room temperature for 5min;

[0041] (3) Add all the mixed solution in tube 1 to tube 2, mix well, and leave at room temperature for 20 min;

[0042] (4) Add the mixed solution in tube 2 dropwise into a 6 cm cell culture dish, shake well, and culture in a cell culture incubator at 37°C and 5% CO2 for 4-6 h;

[0043] (5) Discard the Opti-MEM culture medium containing the transfected plasmid in the culture dish, add 5 ml of the above-mentioned DMEM culture medium, and culture in a cell culture incubator at 37°C and 5% CO2 overnight.

[0044] 3. Transfer cells to a 96-well plate: First, digest the cells with trypsin to remove the cells from the well-walled plate. Then, transfer the fully mixed cell suspension to a 96-well plate and allow it to adhere to the well-walled plate and grow for 6-10 hours.

[0045] 4. Substrate dilution and storage: D-Luciferin was diluted with Opti-MEM medium. The specific dilution method is to add 817μl Opti-MEM medium to a vial containing 25mg D-Luciferin, or add 8.17ml Opti-MEM medium to a vial containing 250mg D-Luciferin, evenly divide into equal parts, and store at -80℃.

[0046] 5. Substrate incubation: Carefully and quickly remove the original DMEM medium from a single well. Quickly add the above DMEM medium containing 2% D-Luciferin dilution to the 96-well plate, 100 μL per well. Incubate in a 37°C, 5% CO2 cell culture incubator for 1-2 hours.

[0047] 6. Add Forskolin: Add 10ul of 100uM Forskolin solution to each experimental well.

[0048] 7. Sample addition: Add 10ul of 100uM solution of the compound to be tested to each experimental well, and add 10ul of 100uM solution of PDEI (PDE4 inhibitor Rolipram is recommended, which has a more significant effect) to each control well.

[0049] 8. Detection of cell spontaneous luminescence intensity by microplate reader: Transfer the 96-well plate to the microplate reader to measure the cell spontaneous luminescence intensity, compare the luminescence intensity of the small molecule compound group with that of the positive drug group, determine whether the compound can increase the intracellular cAMP level, and detect whether the compound has the possibility of inhibiting PDE activity.

[0050] 9. Protein expression and purification: construct recombinant plasmids encoding different PDE subtypes, make them highly express PDE proteins of each subtype in Escherichia coli, and use protein purification technology to obtain protein monomers of each subtype.

[0051] 10. Determination of cAMP concentration: The obtained active compounds are allowed to act on each subtype of PDE protein, and the amount of hydrolyzed substrate cAMP is determined by HPLC technology to determine whether the activity of the compound is due to the inhibition of PDE activity, and then determine the selectivity of the active compound for each subtype.

[0052] (II) Construction of a cell model expressing luciferase that can specifically bind to cGMP to screen for cGMP-specific PDE inhibitors:

[0053] 1. Cell culture: The frozen HEK293T cells were revived and cultured in high-glucose DMEM (containing 10% FBS + 1% double antibody) medium. After 2-3 days of trypsin digestion and passage, the cells were cultured in 6 cm culture dishes when they were in good condition.

[0054] 2. Cell plasmid transfection: When the cells are about 40%-60% confluent in the culture dish, perform plasmid transfection.

[0055] (1) Take 50ul of Opti-MEM culture medium and mix with 4ul of lipofectamine 2000 reagent, mark it as tube 1, and leave it at room temperature for 5 minutes;

[0056] (2) Mix 50 μl of Opti-MEM culture medium and 10 μl of pGloSensor-40F cGMP plasmid (concentration is about 1000 ng / μL), mark it as tube 2, and place it at room temperature for 5 min;

[0057] (3) Add all the mixed solution in tube 1 to tube 2, mix well, and leave at room temperature for 20 min;

[0058] (4) Add the mixed solution in tube 2 dropwise into a 6 cm cell culture dish, shake well, and culture in a cell culture incubator at 37°C and 5% CO2 for 4-6 h;

[0059] (5) Discard the Opti-MEM medium containing the transfected plasmid in the culture dish, add 5 ml of the above DEME medium, and culture in a cell culture incubator at 37°C and 5% CO2 overnight.

[0060] 3. Transfer cells to a 96-well plate: First, digest the cells with trypsin to remove the cells from the well-walled plate. Then, transfer the fully mixed cell suspension to a 96-well plate and allow it to adhere to the well-walled plate and grow for 6-10 hours.

[0061] 4. Substrate dilution and storage: D-Luciferin was diluted with Opti-MEM medium. The specific dilution method is to add 817μl Opti-MEM medium to a vial containing 25mg D-Luciferin, or add 8.17ml Opti-MEM medium to a vial containing 250mg D-Luciferin, evenly divide into equal parts, and store at -80℃.

[0062] 5. Substrate incubation: Carefully and quickly remove the original DMEM medium from a single well. Quickly add the above DMEM medium containing 2% D-Luciferin dilution to the 96-well plate, 100 μL per well. Incubate in a 37°C, 5% CO2 cell culture incubator for 1-2 hours.

[0063] 6. Add S-Nitroso-N-acetyl-DL-penicillamine (SNAP): Add 10ul of 250uM SNAP solution to each experimental well to increase the background cGMP level in the cells.

[0064] 7. Sample addition: Add 10ul of 100uM solution of the compound to be tested to each experimental well, and add 10ul of 100uM solution of PDEI (PDE5 inhibitor Sildenafil is recommended, which has a more significant effect) to each control well.

[0065] 8. Detection of cell spontaneous luminescence intensity by microplate reader: Transfer the 96-well plate to the microplate reader to measure the cell spontaneous luminescence intensity, compare the luminescence intensity of the small molecule compound group with that of the positive drug group, determine whether the compound can increase the intracellular cGMP level, and detect whether the compound has the possibility of inhibiting PDE activity.

[0066] 9. Protein expression and purification: construct recombinant plasmids encoding different PDE subtypes, make them highly express PDE proteins of each subtype in Escherichia coli, and use protein purification technology to obtain protein monomers of each subtype.

[0067] 10. Determination of cGMP concentration: The obtained active compound is allowed to act on each subtype of PDE protein, and the amount of hydrolyzed substrate cGMP is determined by HPLC technology to determine whether the activity of the compound is due to the inhibition of PDE activity, and then determine the selectivity and IC of the active compound for each subtype. 50 .

[0068] 2. Active Drug Screening

[0069] In this embodiment, the above method is used to screen for cAMP or cGMP specific PDE inhibitors:

[0070] (I) Screening of compounds with cAMP-specific PDE inhibitory activity

[0071] In this example, known compounds with PDE inhibitory activity were added according to the above method, and the feasibility of the above screening method was verified by microplate reader detection. The positive compounds used in this example include Rolipram (61413-54-5), Roflumilast (162401-32-3), 3-isobutyl-1-methylxanthine (IBMX, 28822-58-4), Genistein (CAS: 446-72-0), and the results are as follows (the data in each table below are the average values ​​of three parallel tests):

[0072] 1. Rolipram:

[0073] 1) Introduction: Rolipram is a selective phosphodiesterase PDE4 inhibitor with IC50 of 3nM, 130nM and 240nM for PDE4A, PDE4B and PDE4D, respectively.

[0074] 2) Experimental results:

[0075] Table 1

[0076] Element Fluorescence signal PBS (blank control) 14 Rolipram (10 μM) 1131

[0077] Table 2

[0078] Element Fluorescence signal PBS (blank control) 12 Rolipram (10 μM) 1013

[0079] 2. Roflumilast:

[0080] 1) Introduction: Roflumilast is a selective PDE4 inhibitor that acts on PDE4A1, PDEA4, PDEB1 and PDEB2 with IC50 of 0.7, 0.9, 0.7 and 0.2 nM, respectively.

[0081] 2) Experimental results:

[0082] Table 3

[0083]

[0084] Table 4

[0085]

[0086] 3. IBMX:

[0087] 1) Introduction: IBMX, 3-isobutyl-1-methylxanthine, is a non-selective PDE inhibitor with IC50 of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.

[0088] 2) Experimental results:

[0089] Table 5

[0090] Element Fluorescence signal PBS (blank control) 15 IBMX (10 μM) 704

[0091] Table 6

[0092] Element Fluorescence signal PBS (blank control) 21 IBMX (10 μM) 904

[0093] 4. Genistein:

[0094] 1) Introduction: Genistein (genistein, also known as genistein) is a soybean isoflavone that has been reported to have PDE2 inhibitory activity with an IC50 of 1.7 μM

[0095] 2) Experimental results:

[0096] Table 7

[0097] Element Fluorescence signal PBS (blank control) 27 Genistein (50 μM) 490

[0098] Table 8

[0099] Element Fluorescence signal PBS (blank control) 40 Genistein (50 μM) 623

[0100] (II) Screening of compounds with cGMP-specific PDE inhibitory activity

[0101] The positive compounds used in this example include sildenafil (139755-83-2) and 3-isobutyl-1-methylxanthine (IBMX, 28822-58-4). The test results are as follows (the data in each table below are the average values ​​of three parallel tests):

[0102] 1. Sildenafil:

[0103] 1) Introduction: It is a potent phosphodiesterase 5 (PDE5) inhibitor with IC50 of 5.22 nM.

[0104] 2) Experimental results:

[0105] Table 9

[0106] Element Fluorescence signal PBS (blank control) 625 Sildenafil (10 μM) 1093

[0107] Table 10

[0108]

[0109]

[0110] 2. IBMX:

[0111] 1) Introduction: It is a broad-spectrum phosphodiesterase (PDE) inhibitor with IC50 values ​​of 6.5, 26.3 and 31.7 μM for inhibiting PDE3, PDE4 and PDE5, respectively.

[0112] 2) Experimental results:

[0113] Table 11

[0114] Element Fluorescence signal PBS (blank control) 609 IBMX (10 μM) 835

[0115] Table 12

[0116] Element Fluorescence signal PBS (blank control) 617 IBMX (10 μM) 976

[0117] It can be seen from the above measurement results that the PDE inhibitory activity of compounds can be effectively distinguished based on the screening method provided by the present invention.

[0118] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A high-throughput screening method for phosphodiesterase inhibitors, characterized in that: The specific steps of the screening method are as follows: (1) constructing an expression vector of a variant luciferase, and transfecting the expression vector into normal cells, wherein the variant luciferase can specifically bind to cAMP or cGMP in the cells; (2) screening a cell line that stably and highly expresses the variant luciferase, adding the test compound for culturing, and detecting the cAMP or cGMP content in the cells; The phosphodiesterase can be divided into 11 subtypes, among which PDE4, 7 and 8 mainly hydrolyze cAMP, PDE5, 6 and 9 specifically hydrolyze cGMP, and other PDEs have no selectivity for either; The screening method is based on screening under conditions where multiple or simultaneous presence of 11 subtypes of phosphodiesterase; The screening method refers to screening inhibitors of relevant phosphodiesterase subtypes having the activity of hydrolyzing cAMP or cGMP; The screening method can effectively distinguish the PDE inhibitory activity of the compounds; During the transfection process of the expression vector, a luciferase substrate and a cAMP or cGMP agonist are added; The cAMP agonist is Forskolin; the cGMP agonist is S-Nitroso-N-acetyl-DL-penicillamine; The forskolin was added by adding 10uL of a 100uM forskolin solution to each experimental well; The S-Nitroso-N-acetyl-DL-penicillamine was added by adding 10uL of SNAP solution with a concentration of 250uM to each experimental well; In step (2): the expression vector is a luciferase expression vector, and the cAMP and cGMP contents are determined by fluorescence intensity detection; The specific detection steps are as follows: adding positive drugs and test compounds to cell lines that highly express cAMP and cGMP, respectively, and comparing the fluorescence intensities of the test compound group and the positive drug group. The higher the fluorescence intensity, the stronger the phosphodiesterase inhibitory activity of the test compound. The screening method also includes the following steps: constructing a recombinant plasmid encoding different PDE subtypes, allowing it to highly express the PDE protein of each subtype in Escherichia coli, and using protein purification technology to obtain monomers of each subtype protein; allowing the active compound obtained by the above-mentioned fluorescence intensity screening to act on the PDE protein of each subtype, and determining the amount of hydrolyzed substrate by HPLC technology, thereby confirming the PDE subtype acted by the compound.

2. The high-throughput screening method for phosphodiesterase inhibitors according to claim 1, characterized in that: The expression vector is a bacterial plasmid, an adenovirus vector or a lentivirus vector, and a plasmid containing a variant luciferase expression cassette is used, and the plasmid can simultaneously achieve luciferase transfection and expression.

3. The high-throughput screening method for phosphodiesterase inhibitors according to claim 1, characterized in that: The luciferase substrate is D-Luciferin, which is diluted with Opti-MEM, added to DMEM culture medium at a volume of 2%, and then added to the transfected cells for culture.

4. The high-throughput screening method for phosphodiesterase inhibitors according to claim 1, characterized in that: The normal cells are human cells, including HEK293T cell lines.

5. The high-throughput screening method for phosphodiesterase inhibitors according to claim 1, characterized in that: The fluorescence intensity is detected by a fluorescence spectrophotometer or an enzyme marker.